Long-term complications of lymphoma and its treatment

Journal of Clinical Oncology

Volumn 29, Issue 14, 2011, Pages 1885-1892

  Ng, Andrea K ^a,b,c   LaCasce, Ann ^a,b,c   Travis, Lois B ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; AMENORRHEA; AZOOSPERMIA; BLADDER CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; ENDOCRINE DISEASE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INFERTILITY; LEUKEMIA; LUNG CANCER; LUNG TOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEMEN ABNORMALITY;

ANTINEOPLASTIC AGENTS; FEMALE; GONADS; HEART DISEASES; HUMANS; LYMPHOMA; MALE; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY;

EID: 79955871916     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.8427     Document Type: Review

References (90)

1. Coory M, Gill D: Decreasing mortality from non-Hodgkin lymphoma in Australia. Intern Med J 38:921-924, 2008
2. Sehn LH, Donaldson J, Chhanabhai M, et al: Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027-5033, 2005 (Pubitemid 46224009)
3. Cosset JM, Henry-Amar M, Meerwaldt JH: Long-term toxicity of early stages of Hodgkin's disease therapy: The EORTC experience - EORTC Lymphoma Cooperative Group. Ann Oncol 2:77-82, 1991 (suppl 2)
4. Hoppe RT: Hodgkin's disease: Complications of therapy and excess mortality. Ann Oncol 8:115-118, 1997
5. Ng AK, Bernardo MV, Weller E, et al: Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors. Blood 100:1989-1996, 2002
6. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al: Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21:3431-3439, 2003 (Pubitemid 46603515)
7. Ng AK, Abramson JS, Digumarthy SR, et al: Case records of the Massachusetts General Hospital: Case 24-2010 - A 56-year-old woman with a history of Hodgkin's lymphoma and sudden onset of dyspnea and shock. N Engl J Med 363:664-675, 2010
8. van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, et al: Leukemia risk following Hodgkin's disease: Relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 12:1063-1073, 1994 (Pubitemid 24145338)
9. Sieber M, Bredenfeld H, Josting A, et al: 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: Results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:1734-1739, 2003 (Pubitemid 46638585)
10. Swerdlow AJ, Barber JA, Hudson GV, et al: Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment. J Clin Oncol 18:498-509, 2000 (Pubitemid 30078531)
11. Dores GM, Metayer C, Curtis RE, et al: Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years. J Clin Oncol 20:3484-3494, 2002
12. van Leeuwen FE, Klokman WJ, Veer MB, et al: Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 18:487-497, 2000 (Pubitemid 30078530)
13. Hodgson DC, Gilbert ES, Dores GM, et al: Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 25:1489-1497, 2007 (Pubitemid 46759253)
14. Aisenberg AC, Finkelstein DM, Doppke KP, et al: High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer 79:1203-1210, 1997 (Pubitemid 27118218)
15. Hancock SL, Donaldson SS, Hoppe RT: Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 11:1208-1215, 1993 (Pubitemid 23199121)
16. Inskip PD, Robison LL, Stovall M, et al: Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol 27:3901-3907, 2009
17. Travis LB, Hill DA, Dores GM, et al: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290:465-475, 2003 (Pubitemid 37430500)
18. van Leeuwen FE, Klokman WJ, Stovall M, et al: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95:971-980, 2003 (Pubitemid 36896714)
19. Travis LB, Hill D, Dores GM, et al: Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 97:1428-1437, 2005 (Pubitemid 41520078)
20. Preston DL, Mattsson A, Holmberg E, et al: Radiation effects on breast cancer risk: A pooled analysis of eight cohorts. Radiat Res 158:220-235, 2002 (Pubitemid 34851818)
21. O'Brien MM, Donaldson SS, Balise RR, et al: Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol 28:1232-1239, 2010
22. De Bruin ML, Dorresteijn LD, van't Veer MB, et al: Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 101:928-937, 2009
23. Franklin J, Pluetschow A, Paus M, et al: Second malignancy risk associated with treatment of Hodgkin's lymphoma: Meta-analysis of the randomised trials. Ann Oncol 17:1749-1760, 2006 (Pubitemid 44884048)
24. Hill DA, Gilbert E, Dores GM, et al: Breast cancer risk following radiotherapy for Hodgkin lymphoma: Modification by other risk factors. Blood 106:3358-3365, 2005 (Pubitemid 41609165)
25. van Leeuwen FE, Klokman WJ, Stovall M, et al: Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 87:1530-1537, 1995
26. Willemze R, Jaffe ES, Burg G, et al: WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005 (Pubitemid 40656118)
27. van den Belt-Dusebout AW, Aleman BM, Besseling G, et al: Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys 75:1420-1429, 2009
28. Gaya AM, Ashford RF: Cardiac complications of radiation therapy. Clin Oncol (R Coll Radiol) 17:153-159, 2005 (Pubitemid 40468480)
29. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al: Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109:1878-1886, 2007
30. Myrehaug S, Pintilie M, Tsang R, et al: Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 49:1486-1493, 2008
31. Hull MC, Morris CG, Pepine CJ, et al: Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 290:2831-2837, 2003 (Pubitemid 37509491)
32. Küpeli S, Hazirolan T, Varan A, et al: Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin's lymphoma. J Clin Oncol 28:1025-1030, 2010
33. Heidenreich PA, Hancock SL, Lee BK, et al: Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 42:743-749, 2003 (Pubitemid 37000197)
34. Swerdlow AJ, Higgins CD, Smith P, et al: Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British cohort study. J Natl Cancer Inst 99:206-214, 2007
35. Myrehaug S, Pintilie M, Yun L, et al: A population-based study of cardiac morbidity among Hodgkin lymphoma patients with pre-existing heart disease. Blood 116:2237-2240, 2010
36. Bowers DC, McNeil DE, Liu Y, et al: Stroke as a late treatment effect of Hodgkin's Disease: A report from the Childhood Cancer Survivor Study. J Clin Oncol 23:6508-6515, 2005 (Pubitemid 46190242)
37. Morris B, Partap S, Yeom K, et al: Cerebrovascular disease in childhood cancer survivors: A Children's Oncology Group Report. Neurology 73:1906-1913, 2009
38. Hirsch A, Vander Els N, Straus DJ, et al: Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 14:1297-1305, 1996 (Pubitemid 26105539)
39. Koh ES, Sun A, Tran TH, et al: Clinical dosevolume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 66:223-228, 2006 (Pubitemid 44175658)
40. Wolkowicz J, Sturgeon J, Rawji M, et al: Bleomycin-induced pulmonary function abnormalities. Chest 101:97-101, 1992
41. Ng AK, Li S, Neuberg D, et al: A prospective study of pulmonary function in Hodgkin's lymphoma patients. Ann Oncol 19:1754-1758, 2008
42. Knobel H, Håvard Loge J, Brit Lund M, et al: Late medical complications and fatigue in Hodgkin's disease survivors. J Clin Oncol 19:3226-3233, 2001 (Pubitemid 32591440)
43. Bonadonna G, Bonfante V, Viviani S, et al: ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Longterm results. J Clin Oncol 22:2835-2841, 2004 (Pubitemid 41079901)
44. Hancock SL, Cox RS, McDougall IR: Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med 325:599-605, 1991
45. Weiss LM, Movahed LA, Warnke RA, et al: Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 320:502-506, 1989 (Pubitemid 19062526)
46. Robison LL, Bhatia S: Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence. Br J Haematol 122:345-359, 2003 (Pubitemid 36951619)
47. Constine LS, Donaldson SS, McDougall IR, et al: Thyroid dysfunction after radiotherapy in children with Hodgkin's disease. Cancer 53:878-883, 1984 (Pubitemid 14183747)
48. De Bruin ML, Huisbrink J, Hauptmann M, et al: Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood 111:101-108, 2008
49. van der Kaaij MA, Heutte N, Le Stang N, et al: Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 25:2825-2832, 2007 (Pubitemid 47134677)
50. Anselmo AP, Cartoni C, Bellantuono P, et al: Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP. Haematologica 75:155-158, 1990 (Pubitemid 20203579)
51. Hodgson DC, Pintilie M, Gitterman L, et al: Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol 25:11-15, 2007 (Pubitemid 46474309)
52. Behringer K, Breuer K, Reineke T, et al: Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 23:7555-7564, 2005 (Pubitemid 46291819)
53. Sieniawski M, Reineke T, Nogova L, et al: Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: A report of the German Hodgkin Study Group (GHSG). Blood 111:71-76, 2008
54. Girinsky T, van der Maazen R, Specht L, et al: Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines. Radiother Oncol 79:270-277, 2006 (Pubitemid 44109907)
55. Engert A, Plütschow A, Eich HT, et al: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640-652, 2010
56. André M, Mounier N, Leleu X, et al: Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: A GELA cohort study on 2837 patients. Blood 103:1222-1228, 2004 (Pubitemid 38168631)
57. Bluhm EC, Ronckers C, Hayashi RJ, et al: Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study. Blood 111:4014-4021, 2008
58. Brennan P, Coates M, Armstrong B, et al: Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia. Br J Cancer 82:1344-1347, 2000 (Pubitemid 30145356)
59. Dong C, Hemminki K: Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer 85:997-1005, 2001
60. Mudie NY, Swerdlow AJ, Higgins CD, et al: Risk of second malignancy after non-Hodgkin's lymphoma: A British Cohort Study. J Clin Oncol 24:1568-1574, 2006 (Pubitemid 46638780)
61. Sacchi S, Marcheselli L, Bari A, et al: Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study. Haematologica 93:398-404, 2008 (Pubitemid 351398641)
62. Travis LB, Curtis RE, Boice JD Jr, et al: Second cancers following non-Hodgkin's lymphoma. Cancer 67:2002-2009, 1991
63. Travis LB, Curtis RE, Glimelius B, et al: Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 87:524-530, 1995
64. Tward JD, Wendland MM, Shrieve DC, et al: The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 107:108-115, 2006 (Pubitemid 43939037)
65. Hemminki K, Lenner P, Sundquist J, et al: Risk of subsequent solid tumors after non-Hodgkin's lymphoma: Effect of diagnostic age and time since diagnosis. J Clin Oncol 26:1850-1857, 2008
66. Dores GM, Cote TR, Travis LB: New malignancies following Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma, in Curtis RE, Freedman DM, Ron E, et al (eds): New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD, National Institutes of Health, National Cancer Institute, NIH publication 05-5302, 2006
67. Greene MH, Young RC, Merrill JM, et al: Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res 43:1891-1898, 1983
68. Travis LB, Weeks J, Curtis RE, et al: Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma. J Clin Oncol 14:565-571, 1996 (Pubitemid 26051022)
69. Travis LB, Curtis RE, Stovall M, et al: Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 86:1450-1457, 1994 (Pubitemid 24317586)
70. McLaughlin P, Estey E, Glassman A, et al: Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 105:4573-4575, 2005 (Pubitemid 40807273)
71. Tam CS, Seymour JF, Prince HM, et al: Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 91:1546-1550, 2006 (Pubitemid 44739896)
72. Boice J Jr: Ionizing radiation, in Schottenfeld D, Fraumeni JF Jr (eds): Cancer Epidemiology and Prevention (ed 3). New York, NY, Oxford University Press, 2006, pp 259-293
73. Teta MJ, Lau E, Sceurman BK, et al: Therapeutic radiation for lymphoma: Risk of malignant mesothelioma. Cancer 109:1432-1438, 2007 (Pubitemid 46466572)
74. Moser EC, Noordijk EM, van Leeuwen FE, et al: Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma: An EORTC cohort study. Haematologica 91:1481-1488, 2006 (Pubitemid 44736114)
75. Lens MB, Newton-Bishop JA: An association between cutaneous melanoma and non-Hodgkin's lymphoma: Pooled analysis of published data with a review. Ann Oncol 16:460-465, 2005 (Pubitemid 40458325)
76. Goggins WB, Finkelstein DM, Tsao H: Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma. Cancer 91:874-880, 2001 (Pubitemid 32173315)
77. Michels SD, McKenna RW, Arthur DC, et al: Therapy-related acute myeloid leukemia and myelodysplastic syndrome: A clinical and morphological study of 65 cases. Blood 65:1364-1372, 1985 (Pubitemid 15057942)
78. Hemminki K, Jiang Y, Steineck G: Skin cancer and non-Hodgkin's lymphoma as second malignancies: Markers of impaired immune function? Eur J Cancer 39:223-229, 2003
79. Adami J, Frisch M, Yuen J, et al: Evidence of an association between non-Hodgkin's lymphoma and skin cancer. BMJ 310:1491-1495, 1995
80. Levi F, Randimbison L, Te VC, et al: Non-Hodgkin's lymphomas, chronic lymphocytic leukaemias and skin cancers. Br J Cancer 74:1847-1850, 1996
81. Moser EC, Noordijk EM, Carde P, et al: Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. Clin Lymphoma Myeloma 6:122-130, 2005
82. Moser EC, Noordijk EM, van Leeuwen FE, et al: Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 107:2912-2919, 2006
83. Hequet O, Le QH, Moullet I, et al: Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 22:1864-1871, 2004
84. Hershman DL, McBride RB, Eisenberger A, et al: Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 26:3159-3165, 2008
85. Hammond CT, Beckjord EB, Arora NK, et al: Non-Hodgkin's lymphoma survivors' fertility and sexual function-related information needs. Fertil Steril 90:1256-1258, 2008
86. Bahadur G, Ozturk O, Muneer A, et al: Semen quality before and after gonadotoxic treatment. Hum Reprod 20:774-781, 2005 (Pubitemid 40425508)
87. Elis A, Tevet A, Yerushalmi R, et al: Fertility status among women treated for aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 47:623-627, 2006
88. Ogilvy-Stuart AL, Shalet SM: Effect of radiation on the human reproductive system. Environ Health Perspect 101:109-116, 1993 (suppl 2) (Pubitemid 23290942)
89. Howell SJ, Shalet SM: Spermatogenesis after cancer treatment: Damage and recovery. J Natl Cancer Inst Monogr 34:12-17, 2005
90. Smith SK, Zimmerman S, Williams CS, et al: Health status and quality of life among non-Hodgkin lymphoma survivors. Cancer 115:3312-3323, 2009